Professional biotech news 2022? BioTech Health X brings you the latest most reliable biotechnology news including breaking news on the latest biotechnology research, emerging companies, biotech acquisitions, funding deals and other industry analysis. Our coverage not only includes study news and site updates from researchers but also financial analysis of the high and low daily market including several of the last market moves, first opening market updates, top share tips and more. Get everything you need delivered straight to your Inbox with our newsletter based on the science research and stories you want to read and follow from our team. Sign up for free today!

Toyobo Co., Ltd. has launched a major U.S. marketing initiative for Nerbridge TM (“the product”, hereafter), a conduit for peripheral nerve regeneration. On January 11, 2022, Toyobo kicked off the sales promotion campaign at a conference jointly held in Carlsbad, California, by three societies – the American Association for Hand Surgery (AAHS), the American Society for Peripheral Nerve (ASPN) and the American Society for Reconstructive Microsurgery (ASRM). The campaign is being conducted in partnership with the exclusive U.S. distributor of Nerbridge TM, Synovis Micro Companies Alliance, Inc. (hereafter Synovis), a subsidiary of Baxter International Inc., a global medtech leader. Toyobo plans to enhance the production capacity of the product by the end of 2025 as well as expanding the scope of its clinical applications. To respond to the increasing demand expected for nerves conduits in the U.S. and elsewhere in the world, Toyobo will strengthen its production and sales capacities, thus becoming the leading company in the nerve conduit business field.

The conference will also discuss what’s on the horizon in DMD treatment. The focus that we had a number of years ago was to accelerate gene therapy to the point where it is today, Kelly said. Miller added that this is extremely valuable information to the families because they’re being faced right now with choices. When Miller’s own son was diagnosed with DMD about 20 years ago, there were no clinical trials available. Now, families are having to make real decisions. ‘Do I put my kid on an approved exon-skipping drug that’s first-generation, or do I wait for a second-generation exon skipping trial? Do I put my son into gene therapy? If we can’t re-dose him because of the current limitations, then what do we do?’ CureDuchenne works with families to present them with a decision tree, showing them available options as well as the pros and cons of each. It’s an exciting time, but it can be a very confusing time for the families right now, she said.

Get up to date information as researchers study the genetic developments, disease, cancer, DNA, proteins, immune systems, and simultaneously discussing the current virus COVID 19 (SARS COV 2) as international researchers study, target and search for what may be produced and needed for useful new breakthroughs. Topics range from companies focused on cardiovascular disease to gene therapy, regenerative biotechnology, pathogens, tissue regeneration and more. See more information on

Physical disability can be very traumatic for a human being. Irrespective of the cause of the disability, it has a deep psychological effect on people’s minds. Since long there have been attempts to recreate the lost limbs or legs. There are two types of passive prosthetics – static and adjustable. In recent years, adjustable passive prosthetics have gained huge popularity among people due to its superior adjustment abilities. Several recognized organizations such as the International Committee of the Red Cross are now actively participating in the production of such passive prosthetics. They are also working in spreading the awareness about the benefits of using these passive prosthetics in developing countries such as Nepal, India, China, and New Zealand among others.